Study supports additional COVID-19 vaccine doses for immunocompromised
In a study of over 89,000 adults hospitalized with COVID-19 symptoms, prior vaccination with two doses of the Pfizer or Moderna vaccine was 77% effective in preventing COVID-19 in immunocompromised patients compared with 90% effective in immunocompetent patients, the Centers for Disease Control and Prevention reported today. The authors recommend three doses and a booster for immunocompromised individuals receiving mRNA COVID-19 vaccines, consistent with CDC recommendations.
Related News Articles
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…